UA81124C2 - Composition for heart disease treatment based on extracts of radix salviae and panax notogingseng roots, method to prepare and uses thereof - Google Patents
Composition for heart disease treatment based on extracts of radix salviae and panax notogingseng roots, method to prepare and uses thereof Download PDFInfo
- Publication number
- UA81124C2 UA81124C2 UAA200501790A UA2005001790A UA81124C2 UA 81124 C2 UA81124 C2 UA 81124C2 UA A200501790 A UAA200501790 A UA A200501790A UA 2005001790 A UA2005001790 A UA 2005001790A UA 81124 C2 UA81124 C2 UA 81124C2
- Authority
- UA
- Ukraine
- Prior art keywords
- ginsenoside
- borneol
- disease
- blood
- treat
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 69
- 239000000284 extract Substances 0.000 title claims abstract description 29
- 238000000034 method Methods 0.000 title claims abstract description 20
- 238000011282 treatment Methods 0.000 title claims description 83
- 208000019622 heart disease Diseases 0.000 title claims description 14
- 235000002791 Panax Nutrition 0.000 title 1
- 241000208343 Panax Species 0.000 title 1
- 229940116229 borneol Drugs 0.000 claims abstract description 81
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 38
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims abstract description 38
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims abstract description 38
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims abstract description 38
- 238000002360 preparation method Methods 0.000 claims abstract description 31
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 107
- 229930182494 ginsenoside Natural products 0.000 claims description 105
- 229940089161 ginsenoside Drugs 0.000 claims description 102
- AIGAZQPHXLWMOJ-UHFFFAOYSA-N Tanshinone I Chemical compound C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 AIGAZQPHXLWMOJ-UHFFFAOYSA-N 0.000 claims description 74
- 239000000243 solution Substances 0.000 claims description 47
- -1 sodium 3,4-dihydroxyphenyl lactate Chemical compound 0.000 claims description 46
- 210000004369 blood Anatomy 0.000 claims description 40
- 239000008280 blood Substances 0.000 claims description 40
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 36
- 208000029078 coronary artery disease Diseases 0.000 claims description 34
- 229930189092 Notoginsenoside Natural products 0.000 claims description 33
- 229930183118 Tanshinone Natural products 0.000 claims description 33
- 239000006187 pill Substances 0.000 claims description 28
- 201000010099 disease Diseases 0.000 claims description 27
- YMGFTDKNIWPMGF-QHCPKHFHSA-N Salvianolic acid A Natural products OC(=O)[C@H](Cc1ccc(O)c(O)c1)OC(=O)C=Cc2ccc(O)c(O)c2C=Cc3ccc(O)c(O)c3 YMGFTDKNIWPMGF-QHCPKHFHSA-N 0.000 claims description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 26
- 238000000605 extraction Methods 0.000 claims description 25
- DOUMFZQKYFQNTF-WUTVXBCWSA-N (R)-rosmarinic acid Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-WUTVXBCWSA-N 0.000 claims description 24
- 206010021143 Hypoxia Diseases 0.000 claims description 24
- 206010002383 Angina Pectoris Diseases 0.000 claims description 23
- 239000008298 dragée Substances 0.000 claims description 23
- 235000002020 sage Nutrition 0.000 claims description 23
- IBGBGRVKPALMCQ-UHFFFAOYSA-N 3,4-dihydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1O IBGBGRVKPALMCQ-UHFFFAOYSA-N 0.000 claims description 22
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 21
- 230000017531 blood circulation Effects 0.000 claims description 21
- 241000208340 Araliaceae Species 0.000 claims description 20
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 20
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 20
- 235000008434 ginseng Nutrition 0.000 claims description 20
- 239000004615 ingredient Substances 0.000 claims description 20
- STCJJTBMWHMRCD-UHFFFAOYSA-N salvianolic acid B Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=O)C=Cc2cc(O)c(O)c3OC(C(C(=O)OC(Cc4ccc(O)c(O)c4)C(=O)O)c23)c5ccc(O)c(O)c5 STCJJTBMWHMRCD-UHFFFAOYSA-N 0.000 claims description 19
- 230000007954 hypoxia Effects 0.000 claims description 18
- 239000007788 liquid Substances 0.000 claims description 18
- ANUBYMNVOPVATP-LKYMKJHQSA-L magnesium;(2r)-2-[(e)-3-[(2s,3s)-3-[(1r)-1-carboxylato-2-(3,4-dihydroxyphenyl)ethoxy]carbonyl-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydro-1-benzofuran-4-yl]prop-2-enoyl]oxy-3-(3,4-dihydroxyphenyl)propanoate Chemical compound [Mg+2].C([C@@H](OC(=O)/C=C/C1=CC=C(C=2O[C@@H]([C@H](C=21)C(=O)O[C@H](CC=1C=C(O)C(O)=CC=1)C([O-])=O)C=1C=C(O)C(O)=CC=1)O)C([O-])=O)C1=CC=C(O)C(O)=C1 ANUBYMNVOPVATP-LKYMKJHQSA-L 0.000 claims description 18
- SNKFFCBZYFGCQN-VWUOOIFGSA-N Lithospermic acid B Natural products C([C@H](C(=O)O)OC(=O)\C=C\C=1C=2[C@H](C(=O)O[C@H](CC=3C=C(O)C(O)=CC=3)C(O)=O)[C@H](OC=2C(O)=CC=1)C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 SNKFFCBZYFGCQN-VWUOOIFGSA-N 0.000 claims description 16
- 201000001320 Atherosclerosis Diseases 0.000 claims description 15
- 229920002472 Starch Polymers 0.000 claims description 15
- 230000006378 damage Effects 0.000 claims description 15
- 239000008107 starch Substances 0.000 claims description 15
- 235000019698 starch Nutrition 0.000 claims description 15
- UOQACNAKSRARLM-UHFFFAOYSA-N (3,4-dihydroxyphenyl) 2-hydroxypropanoate Chemical compound CC(O)C(=O)OC1=CC=C(O)C(O)=C1 UOQACNAKSRARLM-UHFFFAOYSA-N 0.000 claims description 14
- YMGFTDKNIWPMGF-UCPJVGPRSA-N Salvianolic acid A Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C(=C(O)C(O)=CC=1)\C=C\C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 YMGFTDKNIWPMGF-UCPJVGPRSA-N 0.000 claims description 14
- 229930183842 salvianolic acid Natural products 0.000 claims description 14
- 241000196324 Embryophyta Species 0.000 claims description 13
- NFOCYHUCMXEHDG-UHFFFAOYSA-N Monomethyl lithospermate Natural products COC(=O)C1C(C=2C=C(O)C(O)=CC=2)OC(C(=CC=2)O)=C1C=2C=CC(=O)OC(C(O)=O)CC1=CC=C(O)C(O)=C1 NFOCYHUCMXEHDG-UHFFFAOYSA-N 0.000 claims description 13
- 210000004204 blood vessel Anatomy 0.000 claims description 13
- YMGFTDKNIWPMGF-AGYDPFETSA-N 3-(3,4-dihydroxyphenyl)-2-[(e)-3-[2-[(e)-2-(3,4-dihydroxyphenyl)ethenyl]-3,4-dihydroxyphenyl]prop-2-enoyl]oxypropanoic acid Chemical compound C=1C=C(O)C(O)=C(\C=C\C=2C=C(O)C(O)=CC=2)C=1/C=C/C(=O)OC(C(=O)O)CC1=CC=C(O)C(O)=C1 YMGFTDKNIWPMGF-AGYDPFETSA-N 0.000 claims description 12
- ZZAFFYPNLYCDEP-HNNXBMFYSA-N Rosmarinsaeure Natural products OC(=O)[C@H](Cc1cccc(O)c1O)OC(=O)C=Cc2ccc(O)c(O)c2 ZZAFFYPNLYCDEP-HNNXBMFYSA-N 0.000 claims description 12
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 12
- DOUMFZQKYFQNTF-MRXNPFEDSA-N rosemarinic acid Natural products C([C@H](C(=O)O)OC(=O)C=CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-MRXNPFEDSA-N 0.000 claims description 12
- TVHVQJFBWRLYOD-UHFFFAOYSA-N rosmarinic acid Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=Cc2ccc(O)c(O)c2)C=O TVHVQJFBWRLYOD-UHFFFAOYSA-N 0.000 claims description 12
- 239000004480 active ingredient Substances 0.000 claims description 11
- 206010003119 arrhythmia Diseases 0.000 claims description 11
- 206010012601 diabetes mellitus Diseases 0.000 claims description 11
- 239000000945 filler Substances 0.000 claims description 11
- 239000000843 powder Substances 0.000 claims description 11
- 229960003371 protocatechualdehyde Drugs 0.000 claims description 11
- 210000004027 cell Anatomy 0.000 claims description 10
- 206010020772 Hypertension Diseases 0.000 claims description 9
- 208000035475 disorder Diseases 0.000 claims description 9
- 230000004089 microcirculation Effects 0.000 claims description 9
- 239000009643 salvianolate Substances 0.000 claims description 9
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims description 9
- UJZQBMQZMKFSRV-RGKBJLTCSA-N (2s,3s)-4-[(e)-3-[(1r)-1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy]-3-oxoprop-1-enyl]-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydro-1-benzofuran-3-carboxylic acid Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C=2[C@H](C(O)=O)[C@H](OC=2C(O)=CC=1)C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 UJZQBMQZMKFSRV-RGKBJLTCSA-N 0.000 claims description 8
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 8
- 241000186660 Lactobacillus Species 0.000 claims description 8
- UJZQBMQZMKFSRV-PHQFMFTGSA-N Lithospermic acid Natural products O([C@@H](C(=O)O)Cc1cc(O)c(O)cc1)C(=O)/C=C/c1c2[C@@H](C(=O)O)[C@H](c3cc(O)c(O)cc3)Oc2c(O)cc1 UJZQBMQZMKFSRV-PHQFMFTGSA-N 0.000 claims description 8
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 8
- 239000003463 adsorbent Substances 0.000 claims description 8
- 239000003480 eluent Substances 0.000 claims description 8
- 238000010828 elution Methods 0.000 claims description 8
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 8
- 208000010125 myocardial infarction Diseases 0.000 claims description 8
- 208000031225 myocardial ischemia Diseases 0.000 claims description 8
- 239000011347 resin Substances 0.000 claims description 8
- 229920005989 resin Polymers 0.000 claims description 8
- 238000005406 washing Methods 0.000 claims description 8
- 239000000811 xylitol Substances 0.000 claims description 8
- 235000010447 xylitol Nutrition 0.000 claims description 8
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 8
- 229960002675 xylitol Drugs 0.000 claims description 8
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 7
- 230000015572 biosynthetic process Effects 0.000 claims description 7
- 206010008118 cerebral infarction Diseases 0.000 claims description 7
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 7
- 239000011777 magnesium Substances 0.000 claims description 7
- 229910052749 magnesium Inorganic materials 0.000 claims description 7
- 210000000653 nervous system Anatomy 0.000 claims description 7
- 239000002904 solvent Substances 0.000 claims description 7
- HARGZZNYNSYSGJ-UHFFFAOYSA-N 1,2 dihydrotanshinquinone Natural products C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)CO1 HARGZZNYNSYSGJ-UHFFFAOYSA-N 0.000 claims description 6
- PURTYNPVRFEUEN-UHFFFAOYSA-N 1-dehydrotanshinone Natural products C1=CC(C(CC=C2)(C)C)=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 PURTYNPVRFEUEN-UHFFFAOYSA-N 0.000 claims description 6
- SNKFFCBZYFGCQN-UHFFFAOYSA-N 2-[3-[3-[1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy]carbonyl-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydro-1-benzofuran-4-yl]prop-2-enoyloxy]-3-(3,4-dihydroxyphenyl)propanoic acid Chemical compound C=1C=C(O)C=2OC(C=3C=C(O)C(O)=CC=3)C(C(=O)OC(CC=3C=C(O)C(O)=CC=3)C(O)=O)C=2C=1C=CC(=O)OC(C(=O)O)CC1=CC=C(O)C(O)=C1 SNKFFCBZYFGCQN-UHFFFAOYSA-N 0.000 claims description 6
- 206010002660 Anoxia Diseases 0.000 claims description 6
- 241000976983 Anoxia Species 0.000 claims description 6
- HARGZZNYNSYSGJ-JTQLQIEISA-N Dihydrotanshinone I Chemical compound C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2[C@@H](C)CO1 HARGZZNYNSYSGJ-JTQLQIEISA-N 0.000 claims description 6
- 208000007536 Thrombosis Diseases 0.000 claims description 6
- 206010000891 acute myocardial infarction Diseases 0.000 claims description 6
- 230000007953 anoxia Effects 0.000 claims description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 6
- 230000001684 chronic effect Effects 0.000 claims description 6
- 210000004351 coronary vessel Anatomy 0.000 claims description 6
- VPLLTGLLUHLIHA-UHFFFAOYSA-N dicyclohexyl(phenyl)phosphane Chemical compound C1CCCCC1P(C=1C=CC=CC=1)C1CCCCC1 VPLLTGLLUHLIHA-UHFFFAOYSA-N 0.000 claims description 6
- KXNYCALHDXGJSF-UHFFFAOYSA-N dihydroisotanshinone I Natural products CC1=CC=CC2=C(C(C=3OCC(C=3C3=O)C)=O)C3=CC=C21 KXNYCALHDXGJSF-UHFFFAOYSA-N 0.000 claims description 6
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 6
- MONRRGJOOZMWNB-UHFFFAOYSA-N ethyl lithospermate Natural products CCOC(=O)C1C(C=2C=C(O)C(O)=CC=2)OC(C(=CC=2)O)=C1C=2C=CC(=O)OC(C(=O)OC)CC1=CC=C(O)C(O)=C1 MONRRGJOOZMWNB-UHFFFAOYSA-N 0.000 claims description 6
- 210000004185 liver Anatomy 0.000 claims description 6
- XHALVRQBZGZHFE-KRWDZBQOSA-N methyl rosmarinate Natural products COC(=O)[C@H](Cc1ccc(O)c(O)c1)OC(=O)C=Cc2ccc(O)c(O)c2 XHALVRQBZGZHFE-KRWDZBQOSA-N 0.000 claims description 6
- 230000002829 reductive effect Effects 0.000 claims description 6
- XHALVRQBZGZHFE-UHFFFAOYSA-N rosmarinic acid methyl ester Natural products C=1C=C(O)C(O)=CC=1C=CC(=O)OC(C(=O)OC)CC1=CC=C(O)C(O)=C1 XHALVRQBZGZHFE-UHFFFAOYSA-N 0.000 claims description 6
- PKEGICXVZMKJPR-UHFFFAOYSA-N (-)-neocryptotanshinone Natural products C1CCC(C)(C)C2=CC=C(C(C(C(CO)C)=C(O)C3=O)=O)C3=C21 PKEGICXVZMKJPR-UHFFFAOYSA-N 0.000 claims description 5
- NFOCYHUCMXEHDG-PDLQCWERSA-N (2S)-3-(3,4-dihydroxyphenyl)-2-[(E)-3-[(2S,3S)-2-(3,4-dihydroxyphenyl)-7-hydroxy-3-methoxycarbonyl-2,3-dihydro-1-benzofuran-4-yl]prop-2-enoyl]oxypropanoic acid Chemical compound COC(=O)[C@@H]1[C@H](Oc2c1c(\C=C\C(=O)O[C@@H](Cc1ccc(O)c(O)c1)C(O)=O)ccc2O)c1ccc(O)c(O)c1 NFOCYHUCMXEHDG-PDLQCWERSA-N 0.000 claims description 5
- LGZFJHSOBYVDLA-JTQLQIEISA-N 1-hydroxy-2-[(2r)-1-hydroxypropan-2-yl]-8,8-dimethyl-6,7-dihydro-5h-phenanthrene-3,4-dione Chemical compound C1CCC(C)(C)C=2C1=C1C(=O)C(=O)C([C@H](CO)C)=C(O)C1=CC=2 LGZFJHSOBYVDLA-JTQLQIEISA-N 0.000 claims description 5
- 208000024827 Alzheimer disease Diseases 0.000 claims description 5
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 5
- 208000007882 Gastritis Diseases 0.000 claims description 5
- 206010051151 Hyperviscosity syndrome Diseases 0.000 claims description 5
- 206010033645 Pancreatitis Diseases 0.000 claims description 5
- GCJWPRRNLSHTRY-UHFFFAOYSA-N Salvianolic acid C Natural products C=1C=C(O)C=2OC(C=3C=C(O)C(O)=CC=3)=CC=2C=1C=CC(=O)OC(C(=O)O)CC1=CC=C(O)C(O)=C1 GCJWPRRNLSHTRY-UHFFFAOYSA-N 0.000 claims description 5
- GCJWPRRNLSHTRY-VURDRKPISA-N Salvianolic acid C Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C=2C=C(OC=2C(O)=CC=1)C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 GCJWPRRNLSHTRY-VURDRKPISA-N 0.000 claims description 5
- 208000007718 Stable Angina Diseases 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 5
- 238000009835 boiling Methods 0.000 claims description 5
- YAXTXMBBIHBGPZ-DFCKQENNSA-N dimethyl lithospermate Natural products COC(=O)[C@H](Cc1ccc(O)c(O)c1)OC(=O)C=Cc2ccc(O)c3O[C@H]([C@H](C(=O)OC)c23)c4ccc(O)c(O)c4 YAXTXMBBIHBGPZ-DFCKQENNSA-N 0.000 claims description 5
- 238000000227 grinding Methods 0.000 claims description 5
- 229930195208 isotanshinone Natural products 0.000 claims description 5
- 210000003734 kidney Anatomy 0.000 claims description 5
- YAXTXMBBIHBGPZ-ZBBBDWFHSA-N methyl (2s,3s)-2-(3,4-dihydroxyphenyl)-4-[(e)-3-[(2r)-3-(3,4-dihydroxyphenyl)-1-methoxy-1-oxopropan-2-yl]oxy-3-oxoprop-1-enyl]-7-hydroxy-2,3-dihydro-1-benzofuran-3-carboxylate Chemical compound C([C@H](C(=O)OC)OC(=O)\C=C\C=1C=2[C@H](C(=O)OC)[C@H](OC=2C(O)=CC=1)C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 YAXTXMBBIHBGPZ-ZBBBDWFHSA-N 0.000 claims description 5
- 238000007254 oxidation reaction Methods 0.000 claims description 5
- 229910052760 oxygen Inorganic materials 0.000 claims description 5
- 239000001301 oxygen Substances 0.000 claims description 5
- 239000000419 plant extract Substances 0.000 claims description 5
- 210000001525 retina Anatomy 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- 208000011580 syndromic disease Diseases 0.000 claims description 5
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 4
- 102000004895 Lipoproteins Human genes 0.000 claims description 4
- 108090001030 Lipoproteins Proteins 0.000 claims description 4
- 208000009525 Myocarditis Diseases 0.000 claims description 4
- 206010028851 Necrosis Diseases 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- 208000012886 Vertigo Diseases 0.000 claims description 4
- 230000006793 arrhythmia Effects 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- 208000023652 chronic gastritis Diseases 0.000 claims description 4
- 238000011161 development Methods 0.000 claims description 4
- 239000000499 gel Substances 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 230000017074 necrotic cell death Effects 0.000 claims description 4
- 201000001119 neuropathy Diseases 0.000 claims description 4
- 208000020911 optic nerve disease Diseases 0.000 claims description 4
- 230000003647 oxidation Effects 0.000 claims description 4
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 239000002244 precipitate Substances 0.000 claims description 4
- 238000001556 precipitation Methods 0.000 claims description 4
- 238000011084 recovery Methods 0.000 claims description 4
- 208000004644 retinal vein occlusion Diseases 0.000 claims description 4
- 239000000741 silica gel Substances 0.000 claims description 4
- 229910002027 silica gel Inorganic materials 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 4
- 238000004809 thin layer chromatography Methods 0.000 claims description 4
- 231100000889 vertigo Toxicity 0.000 claims description 4
- SOXUSBQFIOBYJU-VPIXDIMLSA-N (2r)-2-[(e)-3-[2-[(e)-3-[(1r)-1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy]-1-(3,4-dihydroxyphenyl)-3-oxoprop-1-en-2-yl]-3,4-dihydroxyphenyl]prop-2-enoyl]oxy-3-(3,4-dihydroxyphenyl)propanoic acid Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C(=C(O)C(O)=CC=1)\C(=C/C=1C=C(O)C(O)=CC=1)C(=O)O[C@H](CC=1C=C(O)C(O)=CC=1)C(O)=O)C1=CC=C(O)C(O)=C1 SOXUSBQFIOBYJU-VPIXDIMLSA-N 0.000 claims description 3
- MZSGWZGPESCJAN-MOBFUUNNSA-N Melitric acid A Natural products O([C@@H](C(=O)O)Cc1cc(O)c(O)cc1)C(=O)/C=C/c1cc(O)c(O/C(/C(=O)O)=C/c2cc(O)c(O)cc2)cc1 MZSGWZGPESCJAN-MOBFUUNNSA-N 0.000 claims description 3
- 208000003435 Optic Neuritis Diseases 0.000 claims description 3
- 206010035664 Pneumonia Diseases 0.000 claims description 3
- XLXWKULPMYZQSQ-UHFFFAOYSA-N Salvianolic acid E Natural products Cc1ccc(CC(OC(=O)C(=Cc2ccc(O)c(O)c2)c3c(O)c(O)ccc3C=CC(=O)OC(Cc4ccc(O)c(O)c4)C(=O)O)C(=O)O)cc1O XLXWKULPMYZQSQ-UHFFFAOYSA-N 0.000 claims description 3
- QKKVSQZGFSNHSR-UHFFFAOYSA-N Salvianolic acid I Natural products OC(=O)C(Cc1ccc(O)cc1O)OC(=O)C=Cc2ccc(OC(=Cc3ccc(O)c(O)c3)C(=O)O)c(O)c2 QKKVSQZGFSNHSR-UHFFFAOYSA-N 0.000 claims description 3
- 208000007814 Unstable Angina Diseases 0.000 claims description 3
- 239000000443 aerosol Substances 0.000 claims description 3
- 206010006451 bronchitis Diseases 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 210000003128 head Anatomy 0.000 claims description 3
- 210000000987 immune system Anatomy 0.000 claims description 3
- 208000017169 kidney disease Diseases 0.000 claims description 3
- 208000019423 liver disease Diseases 0.000 claims description 3
- 210000004072 lung Anatomy 0.000 claims description 3
- MZSGWZGPESCJAN-JKXXRSRDSA-N melitric acid a Chemical compound C=1C=C(O\C(=C/C=2C=C(O)C(O)=CC=2)C(O)=O)C(O)=CC=1/C=C/C(=O)OC(C(=O)O)CC1=CC=C(O)C(O)=C1 MZSGWZGPESCJAN-JKXXRSRDSA-N 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 210000001328 optic nerve Anatomy 0.000 claims description 3
- 208000019553 vascular disease Diseases 0.000 claims description 3
- 208000020084 Bone disease Diseases 0.000 claims description 2
- 208000018152 Cerebral disease Diseases 0.000 claims description 2
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims description 2
- 206010011703 Cyanosis Diseases 0.000 claims description 2
- 102000009123 Fibrin Human genes 0.000 claims description 2
- 108010073385 Fibrin Proteins 0.000 claims description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 2
- 206010019233 Headaches Diseases 0.000 claims description 2
- 208000033463 Ischaemic neuropathy Diseases 0.000 claims description 2
- 208000019693 Lung disease Diseases 0.000 claims description 2
- 208000027530 Meniere disease Diseases 0.000 claims description 2
- 201000007737 Retinal degeneration Diseases 0.000 claims description 2
- 208000006011 Stroke Diseases 0.000 claims description 2
- 244000269722 Thea sinensis Species 0.000 claims description 2
- 208000008445 altitude sickness Diseases 0.000 claims description 2
- 210000002449 bone cell Anatomy 0.000 claims description 2
- 229950003499 fibrin Drugs 0.000 claims description 2
- 231100000869 headache Toxicity 0.000 claims description 2
- 208000002672 hepatitis B Diseases 0.000 claims description 2
- 208000028867 ischemia Diseases 0.000 claims description 2
- 210000003041 ligament Anatomy 0.000 claims description 2
- 230000003211 malignant effect Effects 0.000 claims description 2
- 239000003094 microcapsule Substances 0.000 claims description 2
- 230000007823 neuropathy Effects 0.000 claims description 2
- 210000000496 pancreas Anatomy 0.000 claims description 2
- 238000005325 percolation Methods 0.000 claims description 2
- 210000005259 peripheral blood Anatomy 0.000 claims description 2
- 239000011886 peripheral blood Substances 0.000 claims description 2
- 230000002085 persistent effect Effects 0.000 claims description 2
- 230000035755 proliferation Effects 0.000 claims description 2
- 230000002040 relaxant effect Effects 0.000 claims description 2
- 230000004258 retinal degeneration Effects 0.000 claims description 2
- 239000013049 sediment Substances 0.000 claims description 2
- 210000002460 smooth muscle Anatomy 0.000 claims description 2
- 239000000829 suppository Substances 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 229940098465 tincture Drugs 0.000 claims description 2
- 210000003462 vein Anatomy 0.000 claims description 2
- FEFAIBOZOKSLJR-UHFFFAOYSA-N Miltirone Chemical compound C1CCC(C)(C)C=2C1=C1C(=O)C(=O)C(C(C)C)=CC1=CC=2 FEFAIBOZOKSLJR-UHFFFAOYSA-N 0.000 claims 2
- 206010013012 Dilatation ventricular Diseases 0.000 claims 1
- 206010023204 Joint dislocation Diseases 0.000 claims 1
- 208000020307 Spinal disease Diseases 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 claims 1
- 210000001636 ophthalmic artery Anatomy 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 235000003143 Panax notoginseng Nutrition 0.000 abstract 1
- 241000180649 Panax notoginseng Species 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 42
- 239000003814 drug Substances 0.000 description 32
- 229940079593 drug Drugs 0.000 description 25
- 210000002216 heart Anatomy 0.000 description 19
- 210000004165 myocardium Anatomy 0.000 description 17
- 230000007423 decrease Effects 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 10
- 229960003711 glyceryl trinitrate Drugs 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 9
- 210000003743 erythrocyte Anatomy 0.000 description 9
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 9
- 108050009340 Endothelin Proteins 0.000 description 8
- 102000002045 Endothelin Human genes 0.000 description 8
- 241000700159 Rattus Species 0.000 description 8
- 230000002107 myocardial effect Effects 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 208000002193 Pain Diseases 0.000 description 7
- 230000002776 aggregation Effects 0.000 description 7
- 238000004220 aggregation Methods 0.000 description 7
- 229940093268 isordil Drugs 0.000 description 7
- MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 description 7
- 230000036407 pain Effects 0.000 description 7
- 210000002381 plasma Anatomy 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 230000036772 blood pressure Effects 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 210000001508 eye Anatomy 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 235000019271 petrolatum Nutrition 0.000 description 6
- 230000003405 preventing effect Effects 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 230000033764 rhythmic process Effects 0.000 description 6
- 238000010561 standard procedure Methods 0.000 description 6
- 239000000006 Nitroglycerin Substances 0.000 description 5
- 210000001772 blood platelet Anatomy 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 229940039696 lactobacillus Drugs 0.000 description 5
- 230000036284 oxygen consumption Effects 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 4
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 210000003403 autonomic nervous system Anatomy 0.000 description 4
- 235000019658 bitter taste Nutrition 0.000 description 4
- 229940107131 ginseng root Drugs 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 238000011866 long-term treatment Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000002483 medication Methods 0.000 description 4
- 229960001597 nifedipine Drugs 0.000 description 4
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 4
- 230000002633 protecting effect Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 208000031229 Cardiomyopathies Diseases 0.000 description 3
- 208000002330 Congenital Heart Defects Diseases 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 206010019280 Heart failures Diseases 0.000 description 3
- 102000018697 Membrane Proteins Human genes 0.000 description 3
- 108010052285 Membrane Proteins Proteins 0.000 description 3
- 208000029578 Muscle disease Diseases 0.000 description 3
- 206010033647 Pancreatitis acute Diseases 0.000 description 3
- 206010033799 Paralysis Diseases 0.000 description 3
- 208000025584 Pericardial disease Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 201000003229 acute pancreatitis Diseases 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 208000028831 congenital heart disease Diseases 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000008121 dextrose Substances 0.000 description 3
- 230000004217 heart function Effects 0.000 description 3
- 208000018578 heart valve disease Diseases 0.000 description 3
- 230000000302 ischemic effect Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 206010002388 Angina unstable Diseases 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 229940127291 Calcium channel antagonist Drugs 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 208000019695 Migraine disease Diseases 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- 206010061323 Optic neuropathy Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 206010063837 Reperfusion injury Diseases 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 206010039966 Senile dementia Diseases 0.000 description 2
- 208000003443 Unconsciousness Diseases 0.000 description 2
- 201000004810 Vascular dementia Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000000480 calcium channel blocker Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 238000006392 deoxygenation reaction Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000005534 hematocrit Methods 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 239000003547 immunosorbent Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 210000005240 left ventricle Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 206010027599 migraine Diseases 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 210000001331 nose Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 229940069328 povidone Drugs 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000010410 reperfusion Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 238000009662 stress testing Methods 0.000 description 2
- 230000002889 sympathetic effect Effects 0.000 description 2
- 230000002537 thrombolytic effect Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 229960001722 verapamil Drugs 0.000 description 2
- VOZDNCFKGOLECZ-BTVCFUMJSA-N 2-hydroxypropanoic acid;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O VOZDNCFKGOLECZ-BTVCFUMJSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010003225 Arteriospasm coronary Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000003890 Coronary Vasospasm Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- NVTRPRFAWJGJAJ-UHFFFAOYSA-L EDTA monocalcium salt Chemical compound [Ca+2].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O NVTRPRFAWJGJAJ-UHFFFAOYSA-L 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- UFNDONGOJKNAES-UHFFFAOYSA-N Ginsenoside Rb1 Natural products CC(=CCCC(C)(OC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CC(O)C45C)C UFNDONGOJKNAES-UHFFFAOYSA-N 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 241000521257 Hydrops Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000010038 Ischemic Optic Neuropathy Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000006670 Multiple fractures Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010030924 Optic ischaemic neuropathy Diseases 0.000 description 1
- 206010031264 Osteonecrosis Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108050008598 Phosphoesterases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 201000007527 Retinal artery occlusion Diseases 0.000 description 1
- 206010057430 Retinal injury Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001343 alkyl silanes Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 201000007058 anterior ischemic optic neuropathy Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002744 anti-aggregatory effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 210000000544 articulatio talocruralis Anatomy 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 229940019700 blood coagulation factors Drugs 0.000 description 1
- 230000008081 blood perfusion Effects 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 230000001964 calcium overload Effects 0.000 description 1
- 230000008822 capillary blood flow Effects 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000001925 catabolic effect Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 201000005849 central retinal artery occlusion Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 238000007887 coronary angioplasty Methods 0.000 description 1
- 201000011634 coronary artery vasospasm Diseases 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 229960004166 diltiazem Drugs 0.000 description 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000000547 effect on apoptosis Effects 0.000 description 1
- 230000000037 effect on migraine Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical group C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 1
- 108010017796 epoxidase Proteins 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000000105 evaporative light scattering detection Methods 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 235000019850 ferrous citrate Nutrition 0.000 description 1
- 239000011640 ferrous citrate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 210000004904 fingernail bed Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- SSPJYWUVFLPKSH-UHFFFAOYSA-N ginsenoside Km Natural products C1CC(C2(CC(O)C3C(C)(C)C(O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(CO)C)OC1OC(CO)C(O)C(O)C1O SSPJYWUVFLPKSH-UHFFFAOYSA-N 0.000 description 1
- GZYPWOGIYAIIPV-JBDTYSNRSA-N ginsenoside Rb1 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GZYPWOGIYAIIPV-JBDTYSNRSA-N 0.000 description 1
- TXEWRVNOAJOINC-UHFFFAOYSA-N ginsenoside Rb2 Natural products CC(=CCCC(OC1OC(COC2OCC(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CCC45C)C TXEWRVNOAJOINC-UHFFFAOYSA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000005986 heart dysfunction Effects 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 210000002758 humerus Anatomy 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- APVZWAOKZPNDNR-UHFFFAOYSA-L iron(ii) citrate Chemical compound [Fe+2].OC(=O)CC(O)(C([O-])=O)CC([O-])=O APVZWAOKZPNDNR-UHFFFAOYSA-L 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000003593 megakaryocyte Anatomy 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 208000021090 palsy Diseases 0.000 description 1
- 230000004203 pancreatic function Effects 0.000 description 1
- 210000005037 parasympathetic nerve Anatomy 0.000 description 1
- 210000001002 parasympathetic nervous system Anatomy 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000004526 pharmaceutical effect Effects 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 230000008327 renal blood flow Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000009476 short term action Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 238000001256 steam distillation Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 210000002820 sympathetic nervous system Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/210,548 US8486464B2 (en) | 2000-12-22 | 2002-07-31 | Herbal composition for angina pectoris, method to prepare same and uses thereof |
| PCT/IB2003/003774 WO2004012651A2 (en) | 2002-07-31 | 2003-07-31 | Composition for heart disease, method to prepare same and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA81124C2 true UA81124C2 (en) | 2007-12-10 |
Family
ID=30443688
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA200501790A UA81124C2 (en) | 2002-07-31 | 2003-07-31 | Composition for heart disease treatment based on extracts of radix salviae and panax notogingseng roots, method to prepare and uses thereof |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US8486464B2 (ko) |
| EP (1) | EP1388344B1 (ko) |
| JP (1) | JP4657714B2 (ko) |
| KR (1) | KR101027230B1 (ko) |
| AU (2) | AU2003227336C1 (ko) |
| BR (1) | BR0302589A (ko) |
| CA (1) | CA2436469C (ko) |
| ES (1) | ES2469490T3 (ko) |
| HK (1) | HK1063284A1 (ko) |
| MX (1) | MXPA03006927A (ko) |
| MY (1) | MY140191A (ko) |
| NZ (2) | NZ527311A (ko) |
| RU (1) | RU2328300C2 (ko) |
| SG (1) | SG116501A1 (ko) |
| UA (1) | UA81124C2 (ko) |
| WO (1) | WO2004012651A2 (ko) |
| ZA (1) | ZA200305860B (ko) |
Families Citing this family (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040202731A1 (en) * | 2003-04-08 | 2004-10-14 | Gow Robert T. | Rosmarinic acid composition |
| US20070059358A1 (en) * | 2003-07-02 | 2007-03-15 | Tianjin Tasly Pharmaceutical Co., Ltd., China | Matrix adjuvants and the drop pills prepared with them |
| US20050037094A1 (en) * | 2003-07-31 | 2005-02-17 | Xijun Yan | Composition for heart disease, its active ingredients, method to prepare same and uses thereof |
| DK1658879T3 (da) * | 2003-08-28 | 2013-05-13 | Tasly Pharmaceutical Group Co | Radix Salviae Miltiorrhizae, ekstrakt og sammensætning deraf til behandling af aspirinresistente sygdomme |
| CN100450501C (zh) * | 2004-03-17 | 2009-01-14 | 天津天士力制药股份有限公司 | 一种治疗心脑血管疾病的中药制剂及其制备方法 |
| CN1771978B (zh) * | 2004-11-09 | 2011-06-08 | 成都华神集团股份有限公司制药厂 | 一种三七三醇皂苷组合物及其制备方法和用途 |
| JP2006298896A (ja) * | 2005-03-22 | 2006-11-02 | Iskra Ind Co Ltd | 高脂血症改善剤、動脈硬化改善剤及び肝機能改善剤 |
| WO2006115321A1 (en) * | 2005-04-25 | 2006-11-02 | Industry Academic Cooperation Foundation, Yeungnam University | Composition comprising the extract of salvia miltiorrhiza bge showing enhancing activity for the prevention or treatment of blood circulatory disease. |
| CA2614700C (en) | 2005-07-14 | 2011-07-19 | National Institute Of Pharmaceutical R&D Co., Ltd. | Medicinal composition containing ginseng secondary glycosides, its preparation method and application |
| KR100703182B1 (ko) * | 2005-08-16 | 2007-04-06 | 건국대학교 산학협력단 | 단삼 추출물을 포함하는 혈전 예방 및 치료를 위한약학조성물 |
| KR100725839B1 (ko) * | 2005-10-06 | 2007-12-11 | 일성신약주식회사 | 단삼으로부터 분리된 탄시논류의 화합물을 함유하는인지기능 장애의 예방 및 치료용 조성물 |
| KR20070040209A (ko) * | 2005-10-11 | 2007-04-16 | 일성신약주식회사 | 단삼 분획물을 함유하는 인지기능 장애의 예방 및 치료용 조성물 |
| KR100773275B1 (ko) * | 2006-05-08 | 2007-11-05 | 건국대학교 산학협력단 | 인삼 사포닌을 유효 성분으로 함유하는 심혈관 질환 치료제및 예방제 |
| KR100830862B1 (ko) | 2006-09-25 | 2008-05-21 | 주식회사 오스코텍 | 진세노사이드 Ｒｂ1을 유효성분으로 포함하는 골 및연골조직 파괴 억제용 조성물 |
| KR101462984B1 (ko) | 2007-08-02 | 2014-11-18 | 타슬리 파마슈티컬 그룹 컴퍼니 리미티드 | 당뇨병 치료용 약학적 조성물 및 이의 제조 방법 |
| CN101861157A (zh) * | 2007-09-14 | 2010-10-13 | 梁旭昇 | 用于评价传统药物的系统和方法 |
| JP5670736B2 (ja) * | 2007-11-12 | 2015-02-18 | コートザイム アンパーツゼルスカブ | エーロゲルを含む防汚組成物 |
| CN102600258A (zh) * | 2008-04-27 | 2012-07-25 | 李生 | 清心安宫丸 |
| US8080582B2 (en) | 2008-08-19 | 2011-12-20 | Scinopharm Taiwan Ltd. | Derivatives of 8-epiblechnic acid and their effects on down-regulation of endothelin (ETA) receptor mRNA |
| EP2415749B1 (en) * | 2009-03-30 | 2016-05-04 | Tasly Pharmaceutical Group Co., Ltd. | New salvianolic acid compound l, preparation method and use thereof |
| CN102071246A (zh) * | 2009-08-27 | 2011-05-25 | 北京科技大学 | 新型中药制剂的开发与评价 |
| CN102100739B (zh) * | 2009-12-17 | 2013-12-25 | 天士力制药集团股份有限公司 | 一种含有丹参素和三七皂苷r1的中药组合物及其应用 |
| CN102160872A (zh) * | 2010-02-23 | 2011-08-24 | 天津天士力制药股份有限公司 | 复方丹参滴丸胶囊 |
| AU2011288044B8 (en) * | 2010-08-06 | 2014-08-07 | Tasly Pharmaceutical Group Co., Ltd. | Use of Salvia miltiorrhiza composition in preparing drugs for secondary prevention of coronary heart disease |
| CN102100363A (zh) * | 2011-01-04 | 2011-06-22 | 中国人民武装警察部队医学院 | 丹参酚酸b在制备抗疲劳保健食品或药物的应用 |
| KR101325832B1 (ko) * | 2011-07-14 | 2013-11-05 | 고완석 | 진세노사이드 Ｒｈ2 성분의 함량이 증가된 흑삼 제조방법 및 그 제조방법에 의해 제조된 흑삼제품 |
| CN102507837A (zh) * | 2011-10-27 | 2012-06-20 | 唐秋海 | 一种降脂通脉胶囊的检测方法 |
| CN102441093A (zh) * | 2011-11-15 | 2012-05-09 | 刘新荣 | 一种降低移植肾动脉阻力指数的药物 |
| CN103191186A (zh) | 2012-01-04 | 2013-07-10 | 天士力制药集团股份有限公司 | 丹参制剂在制备抗肝纤维化药物中的应用 |
| CN102526189B (zh) * | 2012-02-20 | 2013-08-07 | 崔新明 | 一种治疗冠心病心绞痛的中药组合物 |
| CN102614281B (zh) * | 2012-04-23 | 2013-08-28 | 窦媛媛 | 一种提高缺氧耐受力的中药组合物及其制备方法和应用 |
| CN102863328B (zh) * | 2012-05-15 | 2014-11-26 | 北京华素制药股份有限公司 | 一种丹参素的合成方法 |
| CN102688311A (zh) * | 2012-06-26 | 2012-09-26 | 吉林大学珠海学院 | 一种具有降血压作用的中药复方制剂及其制备方法 |
| CN103505489A (zh) * | 2012-06-28 | 2014-01-15 | 天津天狮生物发展有限公司 | 一种含有川芎的中药组合物及制备方法 |
| CN102907673B (zh) * | 2012-10-26 | 2014-08-27 | 中科乐仁（北京）科技发展有限公司 | 对胃黏膜有辅助保护功能的保健食品组合物及其制备方法 |
| CN103006582B (zh) * | 2012-11-20 | 2015-02-18 | 江西青峰药业有限公司 | 一种丹酚酸a冻干粉针及其制备药物用途 |
| CN103536610B (zh) * | 2013-01-09 | 2015-03-11 | 上海中医药大学 | 三七皂苷Fc的医药用途 |
| GEP20186877B (en) | 2013-07-11 | 2018-07-10 | Tasly Pharmaceutical Group Co | Traditional chinese medicine composition, and preparation and application thereof |
| ES2869918T3 (es) | 2013-07-11 | 2021-10-26 | Tasly Pharmaceutical Group Co | Método de preparación de una píldora de microgota de medicina tradicional china y píldora de microgota de medicina tradicional china preparada usando el método |
| EP3020407A4 (en) | 2013-07-11 | 2017-05-03 | Tasly Pharmaceutical Group Co., Ltd. | Traditional chinese medicine composition, and preparation and application thereof |
| CN103399121A (zh) * | 2013-08-20 | 2013-11-20 | 广西迪泰制药有限公司 | 一种中药宁心安神制剂的质量控制方法 |
| CN104418744B (zh) * | 2013-08-29 | 2017-03-01 | 天士力制药集团股份有限公司 | 一种新的丹酚酸化合物t、其制备方法和用途 |
| CN103728383A (zh) * | 2013-12-23 | 2014-04-16 | 广西博科药业有限公司 | 一种药物组合物的质量检测方法 |
| CN103735622A (zh) * | 2014-01-25 | 2014-04-23 | 苏州法莫生物技术有限公司 | 抗原发性高血压药物 |
| US9632069B2 (en) | 2014-02-05 | 2017-04-25 | Vyripharm Llc | Integrated systems and methods of evaluating cannabis and cannabinoid products for public safety, quality control and quality assurance purposes |
| CN103816221A (zh) * | 2014-03-04 | 2014-05-28 | 李燕梅 | 一种治疗高血压的药物 |
| CN103908496B (zh) * | 2014-03-05 | 2017-01-11 | 刘光锋 | 一种治疗心律失常的药物组合物 |
| WO2015159922A1 (ja) * | 2014-04-16 | 2015-10-22 | 花王株式会社 | ニンジン抽出物の製造方法 |
| CN103901136B (zh) * | 2014-04-29 | 2016-03-23 | 广东广发制药有限公司 | 一种快速测定三七药材含量的方法 |
| CN105277643B (zh) * | 2014-07-17 | 2018-10-30 | 天士力医药集团股份有限公司 | 一种用于复方丹参滴丸的一测多评检测方法 |
| CN104225129A (zh) * | 2014-09-03 | 2014-12-24 | 张翠华 | 妇女经期头痛活血行瘀制剂及制备方法 |
| CN104273280A (zh) * | 2014-09-05 | 2015-01-14 | 博白县顿谷镇梁家贵种植场 | 一种活血降脂的保健茶及其制备方法 |
| CN104288639A (zh) * | 2014-09-16 | 2015-01-21 | 上海浦东高星生物技术研究所 | 一种提高记忆力的胶囊剂 |
| CN104374844A (zh) * | 2014-11-13 | 2015-02-25 | 贵州信邦制药股份有限公司 | 丹参药材中水溶性成分的含量测定方法及其应用 |
| CN104483438A (zh) * | 2014-12-22 | 2015-04-01 | 安徽墨药制药有限公司 | 一种八宝五胆药墨的检测方法 |
| CN106138764A (zh) * | 2015-04-01 | 2016-11-23 | 李徵 | 一种治疗冠心病及预防脑中风的纯中药制剂与制备方法 |
| CN106539690B (zh) * | 2015-09-18 | 2020-08-04 | 天士力医药集团股份有限公司 | 一种液体冷却滴丸的连续智能制备方法 |
| CN105301168B (zh) * | 2015-11-17 | 2017-06-30 | 山东沃华医药科技股份有限公司 | 通络化痰胶囊的检测方法 |
| CN105327278A (zh) * | 2015-11-25 | 2016-02-17 | 李涛 | 一种医治肺源性心脏病的制剂及制法 |
| CN111514154A (zh) * | 2015-11-27 | 2020-08-11 | 上海中医药大学 | 三七皂苷Fc治疗脑梗的用途 |
| CN106474430A (zh) * | 2016-12-01 | 2017-03-08 | 辽东学院 | 治疗高血压合并冠心病药物制剂及其制备方法 |
| CN107029053A (zh) * | 2017-02-05 | 2017-08-11 | 田歧都 | 一种治疗冠心病的药物 |
| CN107184841A (zh) * | 2017-06-08 | 2017-09-22 | 王艳华 | 用于治疗心肌炎的中药制剂 |
| CN107281350A (zh) * | 2017-06-27 | 2017-10-24 | 王志高 | 改善血液微循环的中成药及其制备方法 |
| CN107596388B (zh) * | 2017-08-28 | 2021-03-12 | 中山大学 | 一种气虚血瘀证动物模型的制作方法 |
| CN108030089B (zh) * | 2017-10-30 | 2021-06-15 | 浙江科技学院 | 一种丹参水提醇沉药渣回收利用的方法 |
| CN107898816A (zh) * | 2017-12-04 | 2018-04-13 | 中国药科大学 | 眼用药物制剂及其应用 |
| CN108014118B (zh) * | 2017-12-25 | 2019-12-03 | 上海中医药大学 | 一种三七皂苷Ft1的用途 |
| CN108210560B (zh) * | 2018-04-10 | 2021-07-20 | 陕西国际商贸学院 | 一种治疗气虚血瘀症的中药组合物及其制法 |
| CN109060972B (zh) * | 2018-05-16 | 2021-09-24 | 苏州药明泽康生物科技有限公司 | 兔血在制备人疾病体外诊断试剂盒中的应用 |
| CN108619108B (zh) * | 2018-05-29 | 2020-10-09 | 云南永孜堂制药有限公司 | 参七心疏胶囊的应用及其制备方法 |
| CN108949677B (zh) * | 2018-07-05 | 2021-11-30 | 浙江大学 | 地黄苷c和丹酚酸a在促进体外培养骨髓间充质干细胞增殖和抑制复制性衰老中的应用 |
| CN109596754A (zh) * | 2018-07-05 | 2019-04-09 | 广州卡马生物科技有限公司 | 一种丹参对照提取物及其应用 |
| KR102251247B1 (ko) | 2018-08-16 | 2021-05-12 | 유상기 | 협심증 치료용 약학 조성물 및 그 제조방법 |
| CN109406708B (zh) * | 2018-12-14 | 2021-05-25 | 南京海昌中药集团有限公司 | 参蓉健腰酒的薄层测定方法 |
| CN111679012B (zh) * | 2019-07-25 | 2022-03-29 | 通化天实制药有限公司 | 一种丹参提取液及其组合物的制备方法 |
| CN110596266B (zh) * | 2019-09-09 | 2022-04-19 | 西安千禾药业股份有限公司 | 采用hplc-uv法检测葛兰心宁软胶囊中绞股蓝皂苷a的方法 |
| CN111110689B (zh) * | 2020-01-13 | 2021-07-23 | 吉林修正药业新药开发有限公司 | 一种活血化瘀通脉止痛的药物组合物及药物制剂 |
| CN111544419B (zh) * | 2020-06-11 | 2023-06-23 | 王文龙 | 冠心病外用贴膏及其贴膜 |
| JP6967247B1 (ja) * | 2020-06-18 | 2021-11-17 | イスクラ産業株式会社 | 抗マラリア剤 |
| CN112083087A (zh) * | 2020-08-19 | 2020-12-15 | 贵州省农作物品种资源研究所(贵州省现代中药材研究所) | 一种白及提取液获取方法及其操作参数选取方法 |
| CN112315951A (zh) * | 2020-11-02 | 2021-02-05 | 杭州利孚泰生物科技有限公司 | 一种治疗骨关节炎的药物组合物及制备方法和用途 |
| CN115581450B (zh) * | 2022-10-27 | 2023-06-23 | 中国人民解放军陆军军医大学第二附属医院 | 一种基于最大耗氧量和血清指标预测高原头痛的系统 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1467767A1 (de) * | 1965-12-29 | 1968-12-12 | Haessle Ab | Verfahren zur Herstellung stabiler,antacide Verbindungen enthaltender Granulate oder Tabletten |
| US4755504A (en) * | 1985-10-03 | 1988-07-05 | Yaguang Liu | Pharmaceutical composition from Tienchi |
| US4999343A (en) * | 1986-09-22 | 1991-03-12 | Yaguang Liu | Production of polysaccharides and saponin of dangshen |
| US5288485A (en) | 1989-08-31 | 1994-02-22 | Kao Corporation | Vasodilating agent |
| DE4201179A1 (de) | 1992-01-17 | 1993-07-22 | Alfatec Pharma Gmbh | Wirkstoff(e) enthaltendes granulat oder pellet mit einem geruest aus hydrophilen makromolekuelen und verfahren zu seiner herstellung |
| CN1041494C (zh) * | 1993-01-01 | 1999-01-06 | 河南省中药研究所 | 用于治疗慢性缺血性心脏病的一种中药散剂胶囊 |
| JPH06211713A (ja) * | 1993-01-18 | 1994-08-02 | Sansei Seiyaku Kk | 抗アレルギー剤 |
| CN1060399C (zh) | 1993-09-19 | 2001-01-10 | 李云峰 | 护心袋 |
| CN1101556A (zh) * | 1993-10-09 | 1995-04-19 | 周耀群 | 消栓通冲剂及其制备方法 |
| US5589182A (en) | 1993-12-06 | 1996-12-31 | Tashiro; Renki | Compositions and method of treating cardio-, cerebro-vascular and alzheimer's diseases and depression |
| CN1055630C (zh) * | 1996-10-25 | 2000-08-23 | 昆明医学院第一附属医院 | 三七丹参片及其制备方法 |
| CN1058174C (zh) * | 1996-12-24 | 2000-11-08 | 郑袆 | 一种治疗冠心病的药物及其生产方法 |
| US5776463A (en) | 1997-02-19 | 1998-07-07 | Arginteanu; Ronit | Method of reducing stress and circulatory heart disease with freeze-dried borage petal extracts |
| KR100257066B1 (ko) | 1997-10-28 | 2000-05-15 | 김영환 | 에스램(sram)셀의 구조 및 이의 제조방법 |
| CN1069540C (zh) | 1999-08-11 | 2001-08-15 | 河北省药品检验所 | 复方丹参片制取新工艺 |
| KR100341368B1 (ko) * | 1999-08-18 | 2002-06-21 | 김춘란 | 심혈관 질환 치료제의 조성 및 그의 제조방법 |
| CA2434050C (en) | 2000-12-22 | 2014-09-16 | Tianjin Tasly Pharmaceutical Co., Ltd., China | Herbal composition for angina pectoris, method to prepare same and uses thereof |
| CN1161140C (zh) | 2001-11-09 | 2004-08-11 | 天津天士力制药股份有限公司 | 一种预防和治疗冠心病心绞痛的药物及其制备方法和其它用途 |
| KR100421245B1 (ko) | 2000-12-30 | 2004-03-04 | 주식회사 이엠따블유안테나 | 사용가능 주파수 범위 및 이득을 동시에 향상시키는 방법 |
| CN1136895C (zh) | 2001-05-24 | 2004-02-04 | 魏振鸣 | 一种治疗冠心病的药物 |
| CN1337257A (zh) * | 2001-09-20 | 2002-02-27 | 复旦大学 | 复方丹参滴丸在制备抗氧化药物中的应用 |
| US20050037094A1 (en) | 2003-07-31 | 2005-02-17 | Xijun Yan | Composition for heart disease, its active ingredients, method to prepare same and uses thereof |
| CN100450501C (zh) * | 2004-03-17 | 2009-01-14 | 天津天士力制药股份有限公司 | 一种治疗心脑血管疾病的中药制剂及其制备方法 |
-
2002
- 2002-07-31 US US10/210,548 patent/US8486464B2/en not_active Expired - Lifetime
-
2003
- 2003-07-30 ZA ZA200305860A patent/ZA200305860B/xx unknown
- 2003-07-30 EP EP03017260.5A patent/EP1388344B1/en not_active Expired - Lifetime
- 2003-07-30 ES ES03017260.5T patent/ES2469490T3/es not_active Expired - Lifetime
- 2003-07-31 UA UAA200501790A patent/UA81124C2/uk unknown
- 2003-07-31 RU RU2005105931/15A patent/RU2328300C2/ru not_active IP Right Cessation
- 2003-07-31 JP JP2004525710A patent/JP4657714B2/ja not_active Expired - Fee Related
- 2003-07-31 SG SG200304274A patent/SG116501A1/en unknown
- 2003-07-31 NZ NZ527311A patent/NZ527311A/xx not_active IP Right Cessation
- 2003-07-31 AU AU2003227336A patent/AU2003227336C1/en not_active Ceased
- 2003-07-31 MX MXPA03006927A patent/MXPA03006927A/es active IP Right Grant
- 2003-07-31 WO PCT/IB2003/003774 patent/WO2004012651A2/en active Application Filing
- 2003-07-31 MY MYPI20032901A patent/MY140191A/en unknown
- 2003-07-31 AU AU2003253217A patent/AU2003253217A1/en not_active Abandoned
- 2003-07-31 BR BR0302589-6A patent/BR0302589A/pt not_active Application Discontinuation
- 2003-07-31 CA CA2436469A patent/CA2436469C/en not_active Expired - Fee Related
- 2003-07-31 KR KR1020057001718A patent/KR101027230B1/ko active IP Right Grant
- 2003-08-05 NZ NZ527372A patent/NZ527372A/xx not_active IP Right Cessation
-
2004
- 2004-08-11 HK HK04106012.7A patent/HK1063284A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2005539006A (ja) | 2005-12-22 |
| JP4657714B2 (ja) | 2011-03-23 |
| WO2004012651A2 (en) | 2004-02-12 |
| AU2003227336C1 (en) | 2006-02-23 |
| AU2003253217A1 (en) | 2004-02-23 |
| AU2003253217A8 (en) | 2004-02-23 |
| NZ527311A (en) | 2005-04-29 |
| BR0302589A (pt) | 2004-08-31 |
| US8486464B2 (en) | 2013-07-16 |
| KR20050026071A (ko) | 2005-03-14 |
| ES2469490T3 (es) | 2014-06-18 |
| SG116501A1 (en) | 2005-11-28 |
| US20030152651A1 (en) | 2003-08-14 |
| NZ527372A (en) | 2005-04-29 |
| AU2003227336B2 (en) | 2004-12-16 |
| CA2436469A1 (en) | 2004-01-31 |
| AU2003227336A1 (en) | 2004-02-19 |
| WO2004012651A3 (en) | 2004-06-17 |
| MXPA03006927A (es) | 2004-10-15 |
| KR101027230B1 (ko) | 2011-04-06 |
| CA2436469C (en) | 2015-01-13 |
| EP1388344A1 (en) | 2004-02-11 |
| HK1063284A1 (en) | 2004-12-24 |
| RU2005105931A (ru) | 2005-09-10 |
| MY140191A (en) | 2009-11-30 |
| EP1388344B1 (en) | 2014-03-12 |
| ZA200305860B (en) | 2004-05-26 |
| RU2328300C2 (ru) | 2008-07-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2328300C2 (ru) | Композиция для лечения сердечных заболеваний, способ приготовления указанной композиции и ее применение | |
| US8883228B2 (en) | Composition for heart disease, its active ingredients, method to prepare same and uses thereof | |
| US11517604B2 (en) | Method for preparing Plectranthus amboinicus fraction having anti-arthritis activity | |
| CN100404040C (zh) | 一种治疗心脏疾病的药物组合物及其制备方法和用途 | |
| KR100802149B1 (ko) | 혈관 손상에 의한 질환 예방 및 치료용 조성물 | |
| KR101863739B1 (ko) | 치매를 예방하고/하거나 치료하기 위한 약물의 제조에서의 진세노사이드-rg3의 용도 및 약물 | |
| CN105250366B (zh) | 香青兰提取物及其制备方法和用途 | |
| NO160206B (no) | Fremgangsmaate ved fremstilling av isosilybinfri silibinin. | |
| US6329000B1 (en) | Extract of pine needle and the use thereof | |
| CN1698717B (zh) | 一种中药复方脂肪乳注射液及其制备方法 | |
| KR101182199B1 (ko) | 단삼 추출물 또는 크립토탄시논을 유효성분으로 함유하는 뇌졸중의 예방 또는 치료용 조성물 | |
| KR101210405B1 (ko) | 단삼, 그 추출물 및 조성물을 이용한 아스피린 내성 치료제 | |
| US6589572B2 (en) | Hypertension-treatment and cholesterol-depressant composition comprising extract from mixture of Panax notoginseng and Salvia miltiorrhiza and method of preparing the same | |
| CN102228495A (zh) | 一种治疗心脑血管疾病的注射液的制备方法 | |
| CN106880834A (zh) | 一种用于缓解高血压症状的植物精油复合物及制备方法 | |
| CN109172624A (zh) | 一种治疗缺血性脑卒中的药物组合物及其应用 | |
| CN106309943A (zh) | 连葛胶囊及其制备方法 | |
| CN101628022A (zh) | 一种红花滴丸及其制备方法 | |
| CN105663224A (zh) | 一种用于治疗心脑血管疾病的组合物及其制剂 | |
| CN111110790A (zh) | 一种治疗视网膜动脉阻塞的中药组合 | |
| CN112316062A (zh) | 治疗偏头痛的中药组合物、鼻用凝胶剂及制备方法和应用 | |
| CN117860806A (zh) | 通脉护心药物组合物及其制备方法和通脉护心药物 | |
| KR20150046653A (ko) | 과민성 방광 증후군 치료용 조성물 |